NCT01086410 - Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Asthma

Interventions

DRUG

Placebo Inhalation Powder

Placebo Inhalation powder inhaled once daily for 6 weeks' treatment

DRUG

Fluticasone Furoate/GW642444 Inhalation Powder

Dose B inhaled once daily for 6 weeks' treatment

DRUG

Fluticasone Furoate/GW642444 Inhalation Powder

Dose A inhaled once daily for 6 weeks' treatment

DRUG

Placebo Oral Capsule

One placebo capsule taken each day on the last 7 days of the study

DRUG

Prednisolone Oral Capsule

Prednisolone 10mg oral capsule taken each day on the last 7 days of the study

Trial Locations (17)

10117

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

20253

GSK Investigational Site, Hamburg

22927

GSK Investigational Site, Großhansdorf

39112

GSK Investigational Site, Magdeburg

60596

GSK Investigational Site, Frankfurt am Main

73103

GSK Investigational Site, Oklahoma City

78229

GSK Investigational Site, San Antonio

90630

GSK Investigational Site, Cypress

92647

GSK Investigational Site, Huntington Beach

15-010

GSK Investigational Site, Bialystok

80-405

GSK Investigational Site, Gdansk

97-540

GSK Investigational Site, Gidle

31-023

GSK Investigational Site, Krakow

93-513

GSK Investigational Site, Lodz

10-357

GSK Investigational Site, Olsztyn

01-138

GSK Investigational Site, Warsaw